Literature DB >> 19623319

Fibromyalgia syndrome: classification, diagnosis, and treatment.

Winfried Häuser1, Wolfgang Eich, Markus Herrmann, Detlev O Nutzinger, Marcus Schiltenwolf, Peter Henningsen.   

Abstract

BACKGROUND: This S3 guideline takes positions on currently contentious issues in the classification and treatment of fibromyalgia syndrome (FMS).
METHODS: A panel of experts from 10 specialist societies and patients belonging to 2 patient self-help organizations reviewed a total of approximately 8000 publications. Recommendations were developed according to the suggested procedure for S3 guidelines and were then reviewed and approved by the boards of the participating specialist societies. The steering committee ensured that the literature review and the recommendations were kept up to date.
RESULTS: Because this disorder is defined by its symptoms and signs, rather than by any consistently identifiable bodily lesion, the term "fibromyalgia syndrome" is a more appropriate designation for it than "fibromyalgia." FMS is defined by the criteria of the American College of Rheumatology and is classified as a functional somatic syndrome. FMS is diagnosed from the typical constellation of symptoms and by the exclusion of inflammatory and metabolic diseases that could cause the same symptoms. A stepwise treatment approach in which the patient and the physician decide jointly on the treatment options is recommended. The most strongly recommended forms of treatment are aerobic exercise, amitriptyline, cognitive behavioral therapy, and spa therapy.
CONCLUSIONS: The guideline recommendations are intended to promote more effective treatment of this disorder.

Entities:  

Keywords:  diagnosis; fibromyalgia; functional somatic syndrome; guideline; treatment

Mesh:

Year:  2009        PMID: 19623319      PMCID: PMC2712241          DOI: 10.3238/arztebl.2009.0383

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  45 in total

Review 1.  "Fibromyalgia" and the medicalization of misery.

Authors:  Nortin M Hadler
Journal:  J Rheumatol       Date:  2003-08       Impact factor: 4.666

2.  Stop using the American College of Rheumatology criteria in the clinic.

Authors:  Frederick Wolfe
Journal:  J Rheumatol       Date:  2003-08       Impact factor: 4.666

3.  [Fibromyalgia--is it a disease?--contra].

Authors:  I Gralow
Journal:  Dtsch Med Wochenschr       Date:  2004-06-04       Impact factor: 0.628

4.  [Fibromyalgia--is it a disease?--pro].

Authors:  W Müller; T Stratz
Journal:  Dtsch Med Wochenschr       Date:  2004-06-04       Impact factor: 0.628

5.  Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials.

Authors:  Winfried Häuser; Kathrin Bernardy; Bernhard Arnold; Martin Offenbächer; Marcus Schiltenwolf
Journal:  Arthritis Rheum       Date:  2009-02-15

Review 6.  Chronic widespread pain and fibromyalgia: what we know, and what we need to know.

Authors:  Daniel J Clauw; Leslie J Crofford
Journal:  Best Pract Res Clin Rheumatol       Date:  2003-08       Impact factor: 4.098

Review 7.  The epidemiology of chronic generalized musculoskeletal pain.

Authors:  Jan Tore Gran
Journal:  Best Pract Res Clin Rheumatol       Date:  2003-08       Impact factor: 4.098

Review 8.  [Fibromyalgia].

Authors:  W Biewer; I Conrad; W Häuser
Journal:  Schmerz       Date:  2004-04       Impact factor: 1.107

9.  Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review.

Authors:  Peter Henningsen; Thomas Zimmermann; Heribert Sattel
Journal:  Psychosom Med       Date:  2003 Jul-Aug       Impact factor: 4.312

10.  Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials.

Authors:  Winfried Häuser; Kathrin Bernardy; Nurcan Uçeyler; Claudia Sommer
Journal:  Pain       Date:  2009-06-17       Impact factor: 6.961

View more
  26 in total

Review 1.  Efficacy and safety of meditative movement therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jost Langhorst; Petra Klose; Gustav J Dobos; Kathrin Bernardy; Winfried Häuser
Journal:  Rheumatol Int       Date:  2012-02-15       Impact factor: 2.631

2.  [Fibromyalgia syndrome guideline: Interim assessment].

Authors:  M Settan; S Eis; W Häuser
Journal:  Schmerz       Date:  2012-06       Impact factor: 1.107

3.  [The G-DRG System 2009--relevant changes for rheumatology].

Authors:  W Fiori; A Liedtke-Dyong; H-J Lakomek; K Buscham; H Lehmann; W Liman; A-K Fuchs; F Bessler; N Roeder
Journal:  Z Rheumatol       Date:  2010-05       Impact factor: 1.372

4.  [G-DRG system 2009: relevant changes for rheumatology].

Authors:  W Fiori; A Liedtke-Dyong; H-J Lakomek; K Buscham; H Lehmann; W Liman; A-K Fuchs; F Bessler; N Roeder
Journal:  Z Rheumatol       Date:  2009-08       Impact factor: 1.372

5.  Meager result.

Authors:  Matthias Mindach
Journal:  Dtsch Arztebl Int       Date:  2009-10-30       Impact factor: 5.594

6.  Complex and heterogeneous.

Authors:  Roland Wörz
Journal:  Dtsch Arztebl Int       Date:  2009-10-30       Impact factor: 5.594

7.  Definition should be changed.

Authors:  Eugen Judin
Journal:  Dtsch Arztebl Int       Date:  2009-10-30       Impact factor: 5.594

8.  Functional bowel disorders in adults.

Authors:  Winfried Häuser; Peter Layer; Peter Henningsen; Wolfgang Kruis
Journal:  Dtsch Arztebl Int       Date:  2012-02-03       Impact factor: 5.594

Review 9.  The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis.

Authors:  Winfried Häuser; Frederick Wolfe; Thomas Tölle; Nurcan Uçeyler; Claudia Sommer
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

10.  2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary.

Authors:  Mary-Ann Fitzcharles; Peter A Ste-Marie; Don L Goldenberg; John X Pereira; Susan Abbey; Manon Choinière; Gordon Ko; Dwight E Moulin; Pantelis Panopalis; Johanne Proulx; Yoram Shir
Journal:  Pain Res Manag       Date:  2013 May-Jun       Impact factor: 3.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.